For the quarter ending 2026-03-31, ABUS had $5,698K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 169,695 | -3,756 | -7,742 | -22,003 |
| Depreciation and amortization | - | 363 | - | - |
| Depreciation | -341 | - | 11 | 341 |
| Loss on impairment of leasehold improvements and lab equipment | 0 | 0 | 0 | 2,811 |
| Gain on sale of property and equipment | - | 674 | - | - |
| Stock-based compensation expense | 1,359 | 1,262 | 1,263 | 4,428 |
| Change in fair value of contingent consideration | 209 | -2,657 | 268 | 559 |
| Non-cash royalty revenue | 181 | 259 | 249 | 974 |
| Non-cash interest expense | 17 | 17 | 23 | 55 |
| Net accretion and amortization of investments in marketable securities | 354 | 422 | 541 | 1,386 |
| Accounts receivable | -1,160 | 129 | -120 | -1,384 |
| Increase (decrease) in accounts and other receivables | 178,741 | - | - | - |
| Prepaid expenses and other assets | 195 | -1,298 | -1,040 | 640 |
| Accounts payable and accrued liabilities | -985 | 806 | 145 | -3,056 |
| Change in deferred license revenue | 0 | 0 | 0 | -10,434 |
| Other liabilities | -105 | -177 | -155 | -225 |
| Net cash used in operating activities | -8,110 | -4,680 | -5,817 | -29,140 |
| Proceeds from sale of property and equipment | - | 355 | 0 | 9 |
| Acquisition of property and equipment | - | 0 | 0 | 0 |
| Purchase of investments in marketable securities | 13,800 | 25,547 | 51,300 | 63,214 |
| Disposition of investments in marketable securities | 16,000 | 23,831 | 41,281 | 90,165 |
| Net cash provided by investing activities | 2,199 | -1,361 | -10,019 | 26,960 |
| Issuance of common shares pursuant to the open market sale agreement | - | 0 | 0 | 0 |
| Issuance of common shares pursuant to exercise of stock options | 11,531 | 1,640 | 794 | 3,106 |
| Issuance of common shares pursuant to espp | 88 | 0 | 50 | 131 |
| Net cash provided by financing activities | 11,619 | 1,640 | 844 | 3,237 |
| Effect of foreign exchange rate changes on cash and cash equivalents | -10 | 1 | -12 | 25 |
| Increase in cash and cash equivalents | 5,698 | -4,400 | -15,004 | 1,082 |
| Cash and cash equivalents, beginning of period | 18,008 | 22,408 | 36,330 | - |
| Cash and cash equivalents, end of period | 23,706 | 18,008 | 22,408 | - |
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)